Hovione has expanded its solutions to solve issues of poor bioavailability, patient acceptability and to enable optimal delivery for non-oral routes of administration. The company’s portfolio of services now includes crystal design, particle size reduction to the micro or nano-scale and amorphous solid dispersions. These services are offered from bench to commercial scale and are supplemented with formulation development and clinical manufacture to Phase II.
 
“We are very pleased to offer our customers these technologies. In response to customers’ needs, Hovione is investing in new technologies, many of them capable of handling highly potent compounds. These will help drive compounds with development challenges from early clinical to market,” said Guy Villax, chief executive officer of Hovione.